Sugi Predict

Sugi Predict / Compounds / SCHEMBL1108460

SCHEMBL1108460

SCHEMBL1108460

COc1ccc(F)cc1OCC1(C)NC(=O)NC1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ FFAR1 O14842 1/20 0.41
▸ FFAR4 Q5NUL3 1/20 0.41
▸ AKR1A1 P14550 2/20 0.39
▸ AKR1B1 P15121 2/20 0.39
▸ ADAMTS5 Q9UNA0 7/20 0.39
▸ ADAM17 P78536 6/20 0.39
▸ ADAMTS4 O75173 2/20 0.38
▸ MMP13 P45452 2/20 0.38
▸ MMP1 P03956 1/20 0.38
▸ MMP2 P08253 1/20 0.38
▸ MMP3 P08254 1/20 0.38
▸ MMP9 P14780 1/20 0.38
▸ MMP14 P50281 1/20 0.38
▸ ADAM9 Q13443 1/20 0.38
▸ MMP12 P39900 1/20 0.37
▸ MOGAT2 Q3SYC2 1/20 0.37
▸ CCNT1 O60563 1/20 0.37
▸ CDK9 P50750 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1108498 0.85 SMN1; SMN2 (0.47) SMN1; SMN2NPSR1ADAMTS5ADAM17ADAMTS4
SCHEMBL1108465 0.79 GAA (0.49) SMN1; SMN2NPSR1ADAMTS5ADAM17ADAMTS4
SCHEMBL2893907 0.72 SMN1; SMN2 (0.52) SMN1; SMN2NPSR1ADAM17MMP13MMP1
SCHEMBL1358880 0.71 SMN1; SMN2 (0.47) SMN1; SMN2NPSR1ADAMTS5ADAM17ADAMTS4
SCHEMBL1108471 0.68 ALDH1A1 (0.52) SMN1; SMN2NPSR1ADAMTS5ADAM17ADAMTS4
SCHEMBL1132913 0.68 SMN1; SMN2 (0.47) SMN1; SMN2NPSR1ADAM17MMP13MMP1
SCHEMBL18472613 0.67 NFE2L2 (0.61) FFAR1FFAR4
SCHEMBL166380 0.67 NFE2L2 (0.61) FFAR1FFAR4
SCHEMBL9633635 0.66 TUBB1 (0.54) SMN1; SMN2NPSR1FFAR1FFAR4
SCHEMBL12378824 0.66 SMN1; SMN2 (0.48) SMN1; SMN2NPSR1ADAMTS5ADAM17ADAMTS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153673-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2012-04-10 — — US disclosed
US-8153673-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2012-04-10 — — US disclosed
US-20110003853-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2011-01-06 — — US disclosed
EP-1676846-B1 Hydantoin derivatives as MMP inhibitors ASTRAZENECA AB (SE) 2010-12-29 — — EP disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 — — US disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 — — US disclosed
EP-1370537-B1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2010-10-13 — — EP disclosed
US-7754750-B2 a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) ASTRAZENECA AB (SE) 2010-07-13 — — US disclosed
US-7754750-B2 a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) ASTRAZENECA AB (SE) 2010-07-13 — — US disclosed
US-7666892-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2010-02-23 — — US disclosed
US-20080262045-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-10-23 — — US disclosed
US-20080262045-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-10-23 — — US disclosed
US-7427631-B2 especially as inhibitors of MMP12 ASTRAZENECA AB (SE) 2008-09-23 — — US disclosed
US-7427631-B2 especially as inhibitors of MMP12 ASTRAZENECA AB (SE) 2008-09-23 — — US disclosed
US-20080171882-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-07-17 — — US disclosed
US-20080171882-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-07-17 — — US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 — — US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 — — US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 — — US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003853-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP14 SMN1; SMN2 2584/4885NPSR1 2119/4885FFAR1 4412/4885
US-20100273849-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 SMN1; SMN2 1262/4885NPSR1 375/4885FFAR1 2750/4885
US-20080171882-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP14 SMN1; SMN2 2584/4885NPSR1 2119/4885FFAR1 4412/4885
US-20080262045-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 SMN1; SMN2 1262/4885NPSR1 375/4885FFAR1 2750/4885
US-20040138276-A1 Metalloproteinase inhibitors MMP9, MMP11, MMP7 SMN1; SMN2 1982/4885NPSR1 358/4885FFAR1 2897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.